Alteogen Inc. (196170.KQ) Stock
Alteogen Inc.

Company profile
Alteogen reported revenue of 102.85 billion KRW for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 18.64 billion KRW. Overseas was its largest region in fiscal year 2025, with 94% of revenue. In Q2 2025 it reported a net loss of 33.09 billion KRW, against a net loss of 2.92 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 28.81 billion KRW in fiscal year 2022 to 102.85 billion KRW in fiscal year 2024, 89.0% a year on average. Alteogen reports about 181 full-time employees.
What stands out
- Its net profit margin over the last four reported quarters was 75.5%, against a median of 4.7% for 6 listed companies of similar size in its industry.
- It returned to a profit in fiscal year 2024, 62.25 billion KRW, after 4 years of net losses (3.37 billion KRW in fiscal year 2023).
- Revenue growth picked up in Q2 2025: up 52.4% from a year before, after a rise of 6.6% in fiscal year 2024.
- It spent 24.55 billion KRW on research and development in fiscal year 2024, 23.9% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Alteogen Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Largest shareholders
- Soon-Jae Park19.05 %19.05%
- In-Woo Hyung4.815 %4.82%
- Kissei Pharmaceutical Co., Ltd.0.89%
- Hye-Sin Jung0.7764 %0.78%
- Soo-min Park0.517 %0.52%
Share of the company, as of September 25, 2026
Leadership
- Soon-Jae Park Ph.D. — Chief Executive Officer, 71
- Hang Yeon Kim — CFO & Executive VP, 60
- Vivek B. Shenoy M.B.A., Ph.D. — Chief Business Development Officer
- Sang Woo Kang — Senior Vice President of Management Support Group
- Tae-Yon Chun J.D., Ph.D. — Executive VP & Corporate Alliance Officer, 60
In the news
- High Growth Tech Stocks to Watch in December 2025
- European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
- Exploring Three High Growth Tech Stocks In Asia
- Asian Growth Companies With Strong Insider Ownership In November 2025
How much revenue does Alteogen make?
Alteogen reported 102.85 billion KRW in revenue for fiscal year 2024, up 6.6% from 96.52 billion KRW in fiscal year 2023. In Q2 2025 revenue was 18.64 billion KRW.
Where does Alteogen make most of its revenue?
Overseas: 94% of revenue by region in fiscal year 2025, followed by South Korea (6%).
What companies are similar to Alteogen?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Yuhan Corporation (000100.KS), Hanmi Pharm. Co., Ltd. (128940.KS), Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ).
How does Alteogen's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Alteogen, 75.5%; Yuhan Corporation (000100.KS), 10.4%; Hanmi Pharm. Co., Ltd. (128940.KS), 0.0%; Hanall Biopharma Co., Ltd. (009420.KS), -15.3%; LigaChem Biosciences Inc. (141080.KQ), -180.9%; Hugel, Inc. (145020.KQ), 26.4%; Celltrion Pharm, Inc. (068760.KQ), 9.5%.
Has Alteogen made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 15.82 billion KRW; FY2021, a loss of 6.27 billion KRW; FY2022, a loss of 8.15 billion KRW; FY2023, a loss of 3.37 billion KRW; FY2024, 62.25 billion KRW. It reported a net loss in 4 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Alteogen Inc. (196170.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/196170.KQ